Introduction
============

Esophageal carcinoma is one of the most common malignancies and also remains a leading cause of cancer-related death worldwide.[@b1-ott-11-5171] More than 90% cases present as esophageal squamous cell carcinoma (ESCC) in Asian countries.[@b2-ott-11-5171] China is a high incidence area of esophageal cancer, and mortality rate due to this disease is as high as 15.2/100 thousand.[@b3-ott-11-5171] Esophageal cancer is prone to lymph node metastasis in the early stages of cancer because of its extensive lymphatic drainage network.[@b4-ott-11-5171] The overall survival (OS) of esophageal carcinoma patients remains poor, although some improvements have been achieved in treatment.[@b5-ott-11-5171] Unlike lung carcinoma, ESCC was not a special molecular routine practice for therapy. Therefore, identification of genes responsible for prognosis of ESCC and understanding their clinical significance are critical in the diagnosis and treatment of this cancer.

More and more genes involved in the development and tumorigenesis of ESCC are being identified. *SOX2* was the first identified one, as a 317 amino acid transcription factor containing an HMG domain.[@b6-ott-11-5171] *SOX2* gene is located at chromosome 3q26.33 and is involved in cell proliferation, apoptosis, and differentiation and affects prognosis.[@b7-ott-11-5171],[@b8-ott-11-5171] *SOX2* was recently shown to be found in several malignancies including lung, pancreatic, colon, cervical, and prostate cancers.[@b9-ott-11-5171]--[@b12-ott-11-5171] Furthermore, *SOX2* was reported to be associated with lymph node metastasis in oral squamous cell carcinomas.[@b13-ott-11-5171] Intriguingly, *SOX2* was frequently found in squamous cell carcinomas of various organs.[@b14-ott-11-5171] However, its expression in ESCC was controversial for prognosis.

Cyclin D1, a well-known cell cycle regulator gene, is located at chromosome 11q13.[@b15-ott-11-5171] Cyclin D1 was recognized as a nuclear protein by inactivating the cell cycle suppressive retinoblastoma protein. Ki-67 is a common cell proliferation marker and codes for a 359 KD non-histone nuclear protein.[@b16-ott-11-5171] Ki-67 labeling index was found to be significantly associated with poor prognosis in many malignancies, such as lymphoma,[@b17-ott-11-5171] neuroendocrine tumors,[@b18-ott-11-5171] and bladder cancer.[@b19-ott-11-5171] P53 protein was identified as the classic tumor suppressor gene TP53.[@b20-ott-11-5171] Yao et al[@b21-ott-11-5171] reported that high expression of p53 was associated with poor prognosis in patients with early-stage ESCC. However, the prognostic value of coexpression p53 and Cyclin D1 in ESCC remains unknown.

The present investigation was designed to examine the value of using the combination of p53 and ki-67 or Cyclin D1 in ESCC as prognostic markers. Although some investigations have studied the prognostic value of *SOX2*, no consistent conclusion has been drawn. We aimed to examine the prognostic significance of expression of *SOX2*, Cyclin D1, p53, and ki-67 in ESCC.

Materials and methods
=====================

Patients
--------

This study encompassed a retrospective series of 117 patients identified as having ESCC diagnosed between 2008 and 2014 and treated at the First Affiliated Hospital of Xinjiang Medical University. Ethical approval was obtained from the ethics committee of the First Affiliated Hospital of Xinjiang Medical University. Written informed consent for the scientific use of the tissue samples and medical records were obtained from each patient.

Lymph node biopsy was performed in 43 (36.8%) patients, each of whom had at least 1 positive lymph node. According to lymph node ratios (LNR) previously reported,[@b4-ott-11-5171] the patients were classified into two groups (LNR: \<0.2, LNR: ≥0.2). LNR ≥0.2 was seen in 21 (17.9%) cases. Vascular invasion was present in 28 (23.9%) cases, and perineural invasion was reported in 30 (25.6%) cases.

According to 2010 the American Joint Committee on Cancer TNM classification, 35 (29.9%), 34 (29.1%), 28 (23.9%), and 20 (17.1%) of the ESCC patients had pTNM stage 1, 2, 3, and 4 disease, respectively. 21 (17.9%) had metastasis at the time of last follow-up. The metastatic sites included lung (n=8), liver (n=3), bone (n=2), peritoneum (n=2), mediastinum (n=1), and multiple organ (n=5).

Immunohistochemistry (IHC)
--------------------------

Tissues were fixed in 10% formalin, sectioned at 5 µm, subsequently deparaffinized in xylene, and rehydrated in 100%, 95%, 80%, and 70% ethanol. All tissues were blocked with hydrogen peroxide for 10 min and heated in a microwave for antigen retrieval. After blocking with 1% goat serum, the sections were incubated with primary antibodies *SOX2* (Abcam, Stoke-on-Trent, UK, dilution 1:1,000), ki-67 (Dako, Santa Clara, CA, USA, dilution 1:100), p53 (Dako, dilution 1:100), and Cyclin D1 (Dako, dilution 1:500) for 60 min at 37°C. After washing in PBS, the sections were incubated with secondary antibody for 30 min at 37°C. After using DAB for staining, the section were dehydrated, and tread with xylene.

The cutoff values for positivity were as follows: *SOX2* staining of 50% or more was considered as positive, having \<50% positivity in the tumor samples was considered as negative. Immunoreactivity to Cyclin D1 was "low" if nuclear staining of tumor cells was \<20% (low Cyclin D1) and "high" if ≥20% (high Cyclin D1). p53 was scored depending on the staining intensity (0--3+), as no staining (0), weak (1+), moderate (2+), and strong (3+). Cases with scores of 0--1+ were considerate negative, whereas those with score of 2+-3+ were considered positive. For Ki-67, tumors with nuclear immunoreactivity of 50% or more were considered positive, whereas those with \<50% staining were considered as negative.[@b22-ott-11-5171]

Statistical analysis
--------------------

All statistical analyses were performed using SPSS 14.0 (SPSS Inc, Chicago, IL, USA). The characteristics of the ESCC patients were compared using the *χ*^2^ test. OS and progression-free survival (PFS) were assessed using the Kaplan--Meier method and the log-rank test. Multivariate analysis was carried out using the Cox proportional hazard regression model. *P*\<0.05 was considered to be statistically significant.

Results
=======

Clinicopathologic characteristics
---------------------------------

The demographic data of the 117 patients with ESCC included in the study and the pathological characteristics are summarized in [Table 1](#t1-ott-11-5171){ref-type="table"}. The median age of patients at the time of diagnosis was 62 years (35--83 years). The patients were followed up for a mean of 30 months (range 1--72). 54 (46.1%) patients died during the follow-up period. Of 117 patients, 30 (25.6%) patients received radical surgery and chemotherapy. Nine (7.7%) patients received radical surgery, chemotherapy, and radiotherapy.

Association of *SOX2* and Cyclin D1 expression with clinicopathological parameters in ESCC
------------------------------------------------------------------------------------------

We detected *SOX2*, Cyclin D1, p53, and ki-67 expression in both adjacent normal esophageal mucosa epithelium and ESCC tissues by IHC. We found that those factors were localized in cell nuclei, and representative IHC images of *SOX2*, Cyclin D1, p53, and ki-67 are presented in [Figure 1](#f1-ott-11-5171){ref-type="fig"}. The blank controls for *SOX2*, Cyclin D1, p53, and ki-67 are presented in [Figure 2](#f2-ott-11-5171){ref-type="fig"}.

*SOX2* expression was detected in both adjacent normal esophageal mucosa epithelium and ESCC tissues. *SOX2* was localized in cell nuclei and was mainly expressed in the basal layer of the normal esophageal squamous epithelial. Of the cancer specimens, *SOX2* strong positivity was observed in 46.1% (54/117) of samples, *SOX2* status of the samples is shown in [Figure 1](#f1-ott-11-5171){ref-type="fig"}. To evaluate the role of *SOX2* protein in ESCC progression, we analyzed the association between those protein expression and clinicopathological characteristic in ESCC using Pearson's *χ*^2^ test ([Table 2](#t2-ott-11-5171){ref-type="table"}). We observed that upregulation of *SOX2* was associated with N stage (*p*=0.034), differentiation (*p*=0.003), and ki-67 expression (*p*=0.001).

Cyclin D1 was localized in cell nuclei and was also expressed in basal layer of esophagus. Positive Cyclin D1 expression was seen in 70.1% (82/117) of samples. Notably, high Cyclin D1 was correlated with increased p53 expression (*p*=0.015). There was no significant relationship between Cyclin D1 and other clinicopathological parameters.

p53 and ki-67 were both localized in cell nuclei and expressed in basal layer of the normal esophageal squamous epithelial, respectively. We also analyzed p53 and ki-67 expression and observed these factors to be positive in 54.7% (64/117) and 32.5% (38/117) of samples, respectively. p53 expression was significantly associated with Cyclin D1 (*p*=0.015) and ki-67 (*p*=0.048). However, p53 expression was not correlated with *SOX2* (*p*=0.582).

Association clinical feathers in ESCC with patient survival
-----------------------------------------------------------

OS and PFS were analyzed through Kaplan--Meier plots. Univariate analysis showed that N stage (*p*=0.014), higher pTNM (*p*=0.006), adjuvant therapy (*p*=0.044), presence of venous invasion (*p*=0.015), lymph node metastasis (*p*=0.007), and high expression of P53 (*p*=0.018) were associated with OS ([Table 3](#t3-ott-11-5171){ref-type="table"}). Additionally, increased p53 expression (*p*=0.006) and higher pTNM (*p*=0.0001) were significantly correlated with PFS ([Figure 3](#f3-ott-11-5171){ref-type="fig"}). Lymph node metastasis was not associated with PFS (*p*=0.052). Moreover, ki-67 was not associated with prognosis in both OS and PFS. This was similar to previous reports[@b23-ott-11-5171] that patients receiving both surgery and chemotherapy or radiotherapy showed significantly better prognosis than those only receiving surgery radical (*p*=0.044).

Cox proportional multivariate analysis of relationships between all the significant variables and patient survival are shown in [Table 4](#t4-ott-11-5171){ref-type="table"}. We found that therapy (hazard ratio \[HR\]: 0.490, 95% confidence interval \[CI\]: 0.249--0.964, *p*=0.039), high expression of p53 (HR: 2.697, 95% CI: 1.373--5.299, *p*=0.004), and venous invasion (HR: 2.373, 95% CI: 1.129--4.987, *p*=0.023) were significant independent predictors of OS. However, *SOX2* overexpression was not a significant independent prognostic factor in prognosis of ESCC (*p*=0.103). In the multivariate analysis, higher T stage, pTNM stage, venous invasion, and high p53 expression were also found to be independent factors affecting PFS ([Table 4](#t4-ott-11-5171){ref-type="table"}).

To further confirm the role of *SOX2* expression in ESCC, we analyzed OS and PFS using the Kaplan--Meier method ([Figure 4](#f4-ott-11-5171){ref-type="fig"}). We found that that ESCC patients with negative *SOX2* expression had a shorter OS (*p*=0.021). However, *SOX2* expression was not associated with PFS (*p*=0.224). Next, we used Kaplan--Meier and a log-rank test to analyze OS rate in ESCC after stratification by *SOX2* expression and clinical feathers. *SOX2* expression was significantly correlated with favorable prognosis in the group with age \<65 years (*p*=0.020), tumor size \<4 cm (*p*=0.031), moderate differentiation (*p*=0.018), T2 pathological stage (*p*=0.032), no lymph node metastasis (*p*=0.017), the combination of radical surgery and chemotherapy (*p*=0.017), LNR \>0.2 (*p*=0.026), lower p53 expression (*p*=0.029), and higher Cyclin D1 expression (*p*=0.031). Moreover, *SOX2* expression correlated significant with OS among female patients (*p*=0.027).

The Kaplan--Meier survival analysis with log-rank test showed that high p53 expression was associated with shorter OS and PFS (*p*=0.018 and *p*=0.006, respectively) in ESCC. Notably, the combination of increased p53 and Cyclin D1 was associated with OS and PFS (*p*=0.047 and *p*=0.001, respectively). However, the combination of positive p53 and ki-67 was not associated with OS and PFS (*p*=0.047 and *p*=0.001, respectively, in [Figure 5](#f5-ott-11-5171){ref-type="fig"}). In multivariate analysis, the combination of increased p53 and Cyclin D1 was an independent predictor of poor prognosis of ESCC patients ([Table 4](#t4-ott-11-5171){ref-type="table"}). Next, we found that the combination of p53 and Cyclin D1 was significantly correlated with poor prognosis in radical surgery (*p*=0.020) and in the chemotherapy (*p*=0.020) after stratification.

Discussion
==========

ESCC remains an aggressively and lethal malignant carcinoma. Previous studies have reported that the survival rate at 5 years was 40%.[@b24-ott-11-5171] Thus, it is important to investigate the probable molecular markers to improve the outcome of patients with ESCC.

*SOX2* is an important transcription factor and an embryonic stem cell factor. Several studies found that *SOX2* was expressed in a wide variety of squamous cell carcinomas by promoting tumor growth, invasion, and metastasis.[@b25-ott-11-5171] *SOX2* could promote breast cancer cell proliferation and tumorigenesis in in vivo and vitro studies.[@b26-ott-11-5171] As previously described, high level of *SOX2* is associated with poor prognosis in human oral squamous cell carcinomas.[@b27-ott-11-5171] On the other hand, Maehara et al[@b28-ott-11-5171] demonstrated that reduced expression of *SOX2* was correlated with advanced clinical T stage (*p*=0.003) and poor differentiation (*p*=0.002) of tumors in ESCC patients. Wilbertz et al[@b29-ott-11-5171] also found that overexpression of *SOX2* was correlated with favorable prognosis in lung squamous cell carcinoma. There is still controversy regarding the significance of *SOX2* expression for prognosis.

In the current study, we found that *SOX2* was highly expressed in 46.1% (54/117) of primary ESCC patients. More importantly, we observed that upregulation of *SOX2* was associated with N stage (*p*=0.034), differentiation (*p*=0.003), and ki-67 expression (*p*=0.001). With regard to survival, we found that ESCC patients with high *SOX2* expression had significantly better survival time than those with low *SOX2* expression (*p*=0.021) by Kaplan--Meier analysis. Subgroup analysis found that in the low *SOX2* expression group, receiving both radical surgery and chemotherapy did not lead to any significant survival benefit. Moreover, subgroup analysis showed that *SOX2* expression was correlated with OS (*p*=0.017) among ESCC patients without lymph node metastasis. Similar to the present study, a previous study found that increased *SOX2* expression was significantly associated with absence of clinical lymph node metastasis (*p*=0.011).[@b30-ott-11-5171] However, we found that high *SOX2* expression was not associated with PFS (*p*=0.224). Our findings suggested that *SOX2* might potentially act as a prognostic biomarker in ESCC. However, it is still unclear why the absent *SOX2* was correlated with malignant clinical phenotypes.

p53 protein is located at chromosome 17p13.1 and codes for a 393 amino acid protein. Recent findings have shown that p53 expression is upregulated, statistically significantly, in ESCC when compared with normal esophageal squamous epithelial.[@b31-ott-11-5171] Xu et al[@b32-ott-11-5171] found that higher expression of p53 was correlated with a poorer differentiation level (*p*=0.044) and associated with a more advanced clinical stage (*p*=0.015) among 830 operable ESCC patients. In the present study, we also found that p53 was highly expressed in 54.7% (64/117) of primary ESCC patients. Sankalecha et al[@b33-ott-11-5171] found that over-expression of p53 was associated with increasing TNM stage in 91 ESCC patients. However, we found that the expression of p53 was not associated with pTNM (*p*=0.213). With regard to survival, our study revealed that ESCC patients with p53 overexpression had lower OS and PFS rates than patient without p53 expression. Multivariate analysis demonstrated that p53 expression was an independent predicator for poor prognosis of ESCC patients.

This is the first study reporting that the combination of increased p53 and Cyclin D1 was associated with OS and PFS in ESCC (*p*=0.047 and *p*=0.001, respectively). However, coexpression of increased p53 and ki-67 was not associated with OS and PFS. Recent studies showed that p53 expression could predict cisplatin or 5-fluorouracil treatment outcome in ESCC.[@b23-ott-11-5171],[@b34-ott-11-5171] However, our data showed that Cyclin D1, *SOX2*, p53, and ki-67 were not associated with pTNM (*p*=0.091, *p*=0.385, *p*=0.213, and *p*=0.582, respectively) and treatment (*p*=0.681, *p*=0.806, *p*=0.337, and *p*=0.668, respectively). Next, we used Kaplan--Meier and a log-rank test to analyze OS rate in ESCC after stratification by coexpression of p53 and Cyclin D1. The combination of p53 and Cyclin D1 was significantly correlated with poor prognosis in the radical surgery (*p*=0.020) and in the chemotherapy (*p*=0.020) groups. It was suggested that the combination of p53 and Cyclin D1 could be used as a molecular target for ESCC therapy.

In conclusion, our study found that treatment modality, high expression of p53, and venous invasion were significant independent predictors of OS. We also found that higher T stage, pTNM, venous invasion, and high p53 expression were significantly associated with worse PFS. Notably, high expression level of *SOX2* was associated with favorable prognosis in ESCC. The combination of p53 and Cyclin D1 was significantly correlated with poor prognosis in OS and PFS (*p*=0.047 and *p*=0.001, respectively). Taken together, *SOX2* and p53 could be used as prognostic factors and as targets for molecular targeted therapy in patients with ESCC.

This study was supported by National Natural Science Foundation of China (no 81360303) and State Key Laboratory of Pathogenesis, Prevention and Treatment of High Incidence Diseases in Central Asia Fund (SKL-HIDCA-2017-8). Many thanks go to the members of the research team for the careful guidance and technical support.

**Disclosure**

The authors report no conflicts of interest in this work.

![IHC staining of *SOX2*, Cyclin D1, P53, and KI-67 in ESCC tissues.\
**Notes:** (**A**) In normal esophagus mucosa, *SOX2* is localized to the basal layer (100×). (**B**) Strong positive expression of *SOX2* in ESCC (100×). (**C**) *SOX2* was expressed at a low level in ESCC (100×). (**D**) Cyclin D1 expression in normal esophagus epithelium (100×). (**E**) High expression of Cyclin D1 in ESCC (100×). (**F**) Low expression of Cyclin D1 in ESCC (100×). (**G**) P53 was expressed in adjacent normal esophagus mucosa (100×). (**H**) P53 was strongly positive in ESCC (100×). (**I**) P53 was negative in ESCC (100×). (**J**) In normal esophagus mucosa, ki-67 is localized to the basal layer (100×). (**K**) Ki-67 upregulation in ESCC (100×). (**L**) Low expression of ki-67 in ESCC (100×).\
**Abbreviations:** ESCC, esophageal squamous cell carcinoma; IHC, immunohistochemistry.](ott-11-5171Fig1){#f1-ott-11-5171}

![Blank staining of *SOX2*, Cyclin D1, p53, and Ki-67 in ESCC tissues (100×).\
**Notes:** (**A**) Negative control of *SOX2* in esophagus mucosa; (**B**) Negative control of *SOX2* in ESCC; (**C**) Negative control of Cyclin D1 in esophagus mucosa; (**D**) Negative control of Cyclin D1 in ESCC; (**E**) Negative control of p53 in esophagus mucosa; (**F**) Negative control of p53 in ESCC; (**G**) Negative control of Ki-67 in esophagus mucosa; and (**H**) Negative control of Ki-67 in ESCC.\
**Abbreviation:** ESCC, esophageal squamous cell carcinoma.](ott-11-5171Fig2){#f2-ott-11-5171}

![OS and PFS analysis of patients with ESCC using the Kaplan--Meier method.\
**Notes:** OS according to (**A**) N stage; (**B**) pTNM; (**C**) treatment; (**D**) venous invasion; (**E**) lymph node; (**F**) p53 expression (low vs high). PFS according to (**G**) p53 expression (low vs high); (**H**) pTNM.\
**Abbreviations:** OS, overall survival; PFS, progression-free survival; ESCC, esophageal squamous cell carcinoma.](ott-11-5171Fig3){#f3-ott-11-5171}

###### 

OS and PFS based on *SOX2* expression.

**Notes:** (**A**) OS; (**B**) PFS. The OS of ESCC patients was analyzed using Kaplan--Meier and stratified by *SOX2* expression level. (**C**) Female; (**D**) age \<65 years; (**E**) tumor size \<4 cm; (**F**) moderate differentiation; (**G**) pathological stage: T2; (**H**) absent lymph node metastasis; (**I**) receiving both radical surgery and chemotherapy; (**J**) LNRs ≥0.2; (**K**) low expression of p53; and (**L**) high expression of Cyclin D1.

**Abbreviations:** LNR, lymph node ratio; OS, overall survival; PFS, progression-free survival; ESCC, esophageal squamous cell carcinoma.
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![OS according to combined p53-Cyclin D1 expression.\
**Notes:** (**A**) Combined p53-Ki-67 expression; (**B**) PFS based on combined p53-Cyclin D1 expression; (**C**) coexpression of p53 and Ki-67; (**D**) OS and PFS based on coexpression of p53 and Cyclin D1 stratified by treatment; (**E**) receiving radical surgery treatment; and (**F**) receiving both radical surgery and chemotherapy.\
**Abbreviations:** OS, overall survival; PFS, progression-free survival.](ott-11-5171Fig5){#f5-ott-11-5171}

###### 

General characteristics of ESCC patients

  Characteristics and finding   n=117
  ----------------------------- ------------
  Age (years)                   
   Range                        35--83
   Median                       62.00
  Tumor size (cm)               
   Range                        0.2--8.0
   Median                       3.8
  Gender                        
   Male                         87 (74.4%)
   Female                       30 (25.6%)
  Differentiation               
   Well                         14 (12.0%)
   Moderate                     65 (55.5%)
   Poor                         38 (32.5%)
  Pathological stage            
   T1                           5 (4.3%)
   T2                           55 (47.0%)
   T3                           57 (48.7%)
  Lymph metastasis              
   Negative                     74 (63.2%)
   Positive                     43 (36.8%)
  N stage                       
   N0                           75 (64.1%)
   N1                           22 (18.8%)
   N2                           13 (11.1%)
   N3                           7 (6.0%)
  LNR                           
   \<0.2                        96 (82.1%)
   ≥0.2                         21 (17.9%)
  Venous invasion               
   Negative                     89 (76.1%)
   Positive                     28 (23.9%)
  Perineuronal invasion         
   Negative                     87 (74.4%)
   Positive                     30 (25.6%)
  pTNM                          
   I                            35 (29.9%)
   II                           34 (29.1%)
   III                          28 (23.9%)
   IV                           20 (17.1%)

**Abbreviations:** ESCC, esophageal squamous cell carcinoma; LNR, lymph node ratio.

###### 

Correlation of Cyclin D1, *SOX2*, and p53 expression with clinicopathological features in 117 ESCC patients

  Characteristic          Cyclin D1   *p*-value   *SOX2*   *p*-value   P53   *p*-value             
  ----------------------- ----------- ----------- -------- ----------- ----- ----------- ---- ---- -------
  Gender                                                                                           
   Male                   30          57                   48          39                41   46   
   Female                 5           25          0.104    15          15    0.674       12   18   0.531
  Age (years)                                                                                      
   \<65                   21          47                   39          29                33   35   
   ≥65                    14          35          0.840    24          25    0.453       20   29   0.455
  Tumor size                                                                                       
   \<4 cm                 25          60                   47          38                37   48   
   ≥4 cm                  10          22          0.825    16          16    0.679       16   16   0.540
  Differentiation                                                                                  
   Well                   4           10                   13          1                 7    7    
   Moderate               18          47                   28          37                30   35   
   Poor                   13          25          0.779    22          16    0.003       16   22   0.861
  Lymph node                                                                                       
   Absent                 19          55                   41          33                35   39   
   Present                16          27          0.213    22          21    0.703       18   25   0.569
  N stage                                                                                          
   N0                     19          55                   42          32                35   39   
   N1                     7           18                   9           16                12   13   
   N2                     6           6                    6           6                 4    8    
   N3                     3           3           0.247    6           0     0.034       2    4    0.745
  Pathological stage                                                                               
   T1                     2           3                    2           3                 4    1    
   T2                     15          40                   27          28                23   32   
   T3                     18          39          0.778    34          23    0.436       26   31   0.259
  Venous invasion                                                                                  
   Absent                 26          63                   46          43                39   50   
   Present                9           19          0.815    17          11    0.515       14   14   0.665
  Perineuronal invasion                                                                            
   Absent                 26          61                   46          41                38   49   
   Present                9           21          1.000    17          13    0.833       15   15   0.671
  LNR                                                                                              
   \<0.2                  26          70                   50          46                44   52   
   ≥0.2                   9           12          0.190    13          8     0.475       9    12   1.000
  P53                                                                                              
   Low                    22          31                   27          26                          
   High                   13          51          0.015    36          28    0.582                 
  Ki-67                                                                                            
   Low                    25          54                   51          28                41   38   
   High                   10          28          0.668    12          26    0.001       12   26   0.048
  pTNM                                                                                             
   I                      11          24                   18          17                18   17   
   II                     8           26                   16          18                18   16   
   III                    13          15                   19          9                 8    20   
   IV                     3           17          0.091    10          10    0.385       9    11   0.213
  Therapy                                                                                          
   Surgery                24          52                   40          36                34   42   
   Chemotherapy           7           23                   17          13                15   15   
   Radiotherapy           3           6           0.681    4           5     0.806       2    7    0.337

**Abbreviations:** ESCC, esophageal squamous cell carcinoma; LNR, lymph node ratio.

###### 

Univariate analysis of factors associated with OS and PFS in ESCC patients

  Characteristic                       OS       PFS              
  ------------------------------------ -------- ------- -------- --------
  Gender                                                         
   Male/female                         0.381    0.537   0.314    0.575
  Age, years                                                     
   ≥65/\<65                            2.453    0.117   0.291    0.590
  Size, cm                                                       
   ≥4/\<4                              2.694    1.101   0.465    0.495
  Differentiation                                                
   Poor/moderate/well                  0.278    0.870   0.080    0.961
  Pathological stage                                             
   T1/T2/T3                            0.897    0.639   0.611    0.737
  Venous invasion                                                
   Present/absent                      5.953    0.015   1.751    0.186
  Perineuronal invasion                                          
   Present/absent                      3.080    0.079   0.805    0.370
  Lymph metastasis                                               
   Present/absent                      7.172    0.007   3.264    0.052
  N stage                                                        
   N0/N1/N2/N3                         10.623   0.014   1.863    0.601
  Involved LNR                                                   
   ≥0.2/\<0.2                          3.441    0.064   0.107    0.743
  Therapy                                                        
   Surgery/chemotherapy/radiotherapy   6.233    0.044   0.265    0.876
  pTNM                                                           
   I/II/III/IV                         12.316   0.006   28.801   0.0001
  Ki-67                                                          
   Low/high                            0.779    0.378   0.139    0.709
  P53                                                            
   Low/high                            5.623    0.018   7.621    0.006
  Cyclin D1                                                      
   Low/high                            1.412    0.235   0.933    0.334
  *SOX2*                                                         
   Low/high                            5.291    0.021   1.477    0.224
  P53 + Cyclin D1                                                
   Low/high                            3.949    0.047   11.470   0.001
  P53 + ki-67                                                    
   Low/high                            0.040    0.841   2.080    0.149

**Abbreviations:** ESCC, esophageal squamous cell carcinoma; OS, overall survival; PFS, progression-free survival; LNR, lymph node ratio.

###### 

Multivariate analysis of factors associated with OS and PFS for ESCC

  Characteristic                       OS              PFS                                    
  ------------------------------------ --------------- ------- ------- -------------- ------- --------
  Therapy                                                                                     
   Surgery/chemotherapy/radiotherapy   0.249--0.964    0.490   0.039   0.336--0.960   0.568   0.035
                                                                                              
  Venous invasion                                                                             
   Present/absent                      1.129--4.987    2.373   0.023   1.114--4.269   2.181   0.023
  P53                                                                                         
   Low/high                            1.373--5.299    2.697   0.004   1.222--3.747   2.140   0.008
  *SOX2*                                                                                      
   Low/high                            0.272--1.126    0.553   0.103   0.399--1.239   0.703   0.223
  pTNM                                                                                        
   I/II/III/IV                         0.776--1.603    1.115   0.555   1.592--2.877   2.140   0.0001
  P53 + Cyclin D1                                                                             
   Low/high                            1.184--22.649   5.178   0.029   1.17--14.049   4.057   0.027

**Abbreviations:** CI, confidence interval; ESCC, esophageal squamous cell carcinoma; HR, hazard ratio; OS, overall survival; PFS, progression-free survival.
